Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
Crossref DOI link: https://doi.org/10.1007/s00262-014-1610-3
Published Online: 2014-10-07
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Balasa, Balaji
Yun, Rui
Belmar, Nicole A.
Fox, Melvin
Chao, Debra T.
Robbins, Michael D.
Starling, Gary C.
Rice, Audie G.
License valid from 2014-10-07